1. Product portfolio addressing large and growing markets:

Focusing on becoming a leader in the large and growing space of substance use disorders and mental health. In parallel, Orexo is also addressing the ongoing opioid epidemic, one of the largest health cri­ses to take place in the US and increasingly a growing global concern.

2. Strong cash conversion to support growth:

Lead product ZUBSOLV®, for the treatment of opioid use disorder, is a strong cash and profit contributor, enabling continued investment in on-market products, and R&D.

3. Leveraging our US commercial excellence:

Strategic focus on leveraging its commercial excellence and strong market access network in the US, by adding more products to the US commercial platform.

4. Expanding pipeline targeting unmet medical needs:

Continue to build on the strong experience of developing products with worldwide approval by expanding the pipeline with multiple short-time to market assets based on innovative drug delivery technologies and digital therapies, addressing unmet medical needs in our key therapeutic areas.

5. Entering digital therapeutics, a new evidence-based frontier in patient care:

Digital therapeutics can increase access to treatment and improve treatment outcomes, and is set to become an integral part of the global healthcare landscape. Substance use disorder and mental health are areas where it is most needed.